{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Electroporation+%28EP%29&page=2",
    "query": {
      "intervention": "Electroporation (EP)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Electroporation+%28EP%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Electroporation+%28EP%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T06:32:34.188Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03567720",
      "title": "Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tavokinogene telseplasmid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunopulse",
          "type": "DEVICE"
        },
        {
          "name": "nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine plus carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2018-10-11",
      "completion_date": "2024-09",
      "has_results": false,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03567720"
    },
    {
      "nct_id": "NCT03132675",
      "title": "Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III/IV Melanoma"
      ],
      "interventions": [
        {
          "name": "tavokinogene telseplasmid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ImmunoPulse",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2017-10-03",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Yuma, Arizona • La Jolla, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03132675"
    },
    {
      "nct_id": "NCT03823131",
      "title": "Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ImmunoPulse",
          "type": "DEVICE"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "CORVax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tavokinogene telseplasmid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Chase Heaton, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-05-02",
      "completion_date": "2022-07-31",
      "has_results": true,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823131"
    },
    {
      "nct_id": "NCT00198276",
      "title": "Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "MedPulser Electroporation with bleomycin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2004-02",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198276"
    },
    {
      "nct_id": "NCT02163057",
      "title": "Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Cancer"
      ],
      "interventions": [
        {
          "name": "INO-3112",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CELLECTRA™-5P",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2014-08-13",
      "completion_date": "2017-01-23",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163057"
    },
    {
      "nct_id": "NCT03181789",
      "title": "Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "p24CE1/2 pDNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "p55^gag pDNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 pDNA Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2017-10-18",
      "completion_date": "2020-04-29",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Decatur, Georgia • Cleveland, Ohio",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181789"
    },
    {
      "nct_id": "NCT01859325",
      "title": "Therapeutic Vaccine for HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV",
        "Therapeutic Vaccine"
      ],
      "interventions": [
        {
          "name": "rVSV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 pDNA adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HIV-Mag pDNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2013-05-10",
      "completion_date": "2017-02-26",
      "has_results": true,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859325"
    },
    {
      "nct_id": "NCT04336410",
      "title": "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronavirus Infection"
      ],
      "interventions": [
        {
          "name": "INO-4800",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2020-04-03",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-04-15",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04336410"
    },
    {
      "nct_id": "NCT02654080",
      "title": "Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-1 nef/tat/vif, env pDNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rVSV HIV envC vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2016-03",
      "completion_date": "2019-07-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654080"
    },
    {
      "nct_id": "NCT03180684",
      "title": "Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)",
        "Vulvar Dysplasia",
        "Vulvar Intraepithelial Neoplasia (VIN)",
        "VIN2",
        "VIN3",
        "Pre-cancerous Lesions of the Vulva",
        "Human Papillomavirus (HPV)"
      ],
      "interventions": [
        {
          "name": "VGX-3100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Imiquimod 5% Cream",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA™ 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2017-08-31",
      "completion_date": "2020-12-18",
      "has_results": true,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-09-30T06:32:34.188Z",
      "location_count": 15,
      "location_summary": "Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03180684"
    }
  ]
}